PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19432995-4 2009 The number of T-SPOT.TB positives represents 11% of the individuals defined as recently infected by TST after exposure (3/27) and 2% of the total number of exposed people tested (3/155). Terbium 21-23 thiosulfate sulfurtransferase Homo sapiens 100-103 19432995-5 2009 In addition, 15 individuals had been previously defined as infected by TST before exposure of whom 2 subjects were T-SPOT.TB positive. Terbium 122-124 thiosulfate sulfurtransferase Homo sapiens 71-74 19432995-6 2009 All individuals detected as T-SPOT.TB positive belonged to the TST positive group (> 15 mm), and the percentage concordance between T-SPOT.TB and TST, including both previously and newly infected subjects, was 12% (5/42). Terbium 35-37 thiosulfate sulfurtransferase Homo sapiens 63-66 19146687-11 2009 Finally, both methods agreed well with the TST, k = 0.86 for TST/QuantiFERON-TB Gold and k = 0.76 for TST/T SPOT-TB. Terbium 77-79 thiosulfate sulfurtransferase Homo sapiens 43-46 18853288-7 2008 In multivariate analysis, incidence of TB in country of origin was the strongest predictor of result of TST or T-SPOT.TB. Terbium 39-41 thiosulfate sulfurtransferase Homo sapiens 104-107 18853288-12 2008 Longitudinal data are needed to clarify the risk of TB in T-SPOT.TB+/TST- individuals. Terbium 52-54 thiosulfate sulfurtransferase Homo sapiens 69-72 25318864-10 2015 Each TSPOT(+) and TST(+) results were independently associated with immigrant status and prior residence in a TB prevalent country after adjustment for immunosuppressive therapy: Adjusted OR(TSPOT+)=6.6 (95 % CI, 1.2-123.3; P = .027); and adjusted OR(TST+)=11.2 (95 % CI, 2.0-209.5; P = .003). Terbium 110-112 thiosulfate sulfurtransferase Homo sapiens 18-21 16898373-6 2006 The TST performed poorly in vaccinated persons of all ages from countries of low TB incidence, but was a useful screen for LTBI in vaccinated adults from countries of high and intermediate incidence. Terbium 81-83 thiosulfate sulfurtransferase Homo sapiens 4-7 16898373-9 2006 CONCLUSIONS: The usefulness of the TST as a screening method for LTBI depends on the age of the patient and the incidence of TB in their country of origin. Terbium 66-68 thiosulfate sulfurtransferase Homo sapiens 35-38 12735118-6 2003 New guidelines for the treatment of LTBI emphasize targeted TST among persons at high risk for development of active TB and no longer use age as an exclusionary condition. Terbium 37-39 thiosulfate sulfurtransferase Homo sapiens 60-63 28060926-9 2017 However, keeping in view the cost, and other logistics, TST remains the most preferred method for LTBI diagnosis in resource-limited, high TB-burden settings. Terbium 99-101 thiosulfate sulfurtransferase Homo sapiens 56-59 17089872-4 2006 The diagnosis of TB in most of the world depends on the presence of a clinical illness typical for TB in concert with radiographic changes, the presence of AFB in sputum, or a positive TST. Terbium 17-19 thiosulfate sulfurtransferase Homo sapiens 185-188 30420888-11 2018 Therefore, we suggest that the criterion of a TST reaction of 5 mm to define latent TB infection in our population should be reevaluated. Terbium 84-86 thiosulfate sulfurtransferase Homo sapiens 46-49 25318864-10 2015 Each TSPOT(+) and TST(+) results were independently associated with immigrant status and prior residence in a TB prevalent country after adjustment for immunosuppressive therapy: Adjusted OR(TSPOT+)=6.6 (95 % CI, 1.2-123.3; P = .027); and adjusted OR(TST+)=11.2 (95 % CI, 2.0-209.5; P = .003). Terbium 110-112 thiosulfate sulfurtransferase Homo sapiens 251-254 23593145-11 2013 CONCLUSIONS: Unlike previous studies, TST was the most cost-effective strategy for averting new TB cases in the short term. Terbium 96-98 thiosulfate sulfurtransferase Homo sapiens 38-41 23943073-9 2013 Conversely, lymph node TB (OR = 0.2; 95 % CI 0.1-0.5) and skeletal TB (OR = 0.2; 95 % CI 0.1-0.5) were associated with true-positive TST results. Terbium 23-25 thiosulfate sulfurtransferase Homo sapiens 133-136 23943073-9 2013 Conversely, lymph node TB (OR = 0.2; 95 % CI 0.1-0.5) and skeletal TB (OR = 0.2; 95 % CI 0.1-0.5) were associated with true-positive TST results. Terbium 67-69 thiosulfate sulfurtransferase Homo sapiens 133-136 22120597-1 2012 OBJECTIVE: The purpose of this study was to examine the usefulness of the TST and the interferon-gamma release assays (IGRA) for diagnosing smear-negative pulmonary TB in immunocompromised patients in an intermediate TB burden. Terbium 165-167 thiosulfate sulfurtransferase Homo sapiens 74-77 21980060-7 2012 Of the untreated groups, the rate of progression to TB was higher in the group with TST-positive (TST+) results (6.1%, six of 99) than in that with TST-negative (TST-) results (0.6%, 10 of 1,556; P < .001). Terbium 52-54 thiosulfate sulfurtransferase Homo sapiens 84-87 21980060-7 2012 Of the untreated groups, the rate of progression to TB was higher in the group with TST-positive (TST+) results (6.1%, six of 99) than in that with TST-negative (TST-) results (0.6%, 10 of 1,556; P < .001). Terbium 52-54 thiosulfate sulfurtransferase Homo sapiens 98-101 21980060-7 2012 Of the untreated groups, the rate of progression to TB was higher in the group with TST-positive (TST+) results (6.1%, six of 99) than in that with TST-negative (TST-) results (0.6%, 10 of 1,556; P < .001). Terbium 52-54 thiosulfate sulfurtransferase Homo sapiens 98-101 21980060-7 2012 Of the untreated groups, the rate of progression to TB was higher in the group with TST-positive (TST+) results (6.1%, six of 99) than in that with TST-negative (TST-) results (0.6%, 10 of 1,556; P < .001). Terbium 52-54 thiosulfate sulfurtransferase Homo sapiens 98-101 21980060-8 2012 Among TST+ contacts, the rate of progression to TB was higher in the group with QFT-G-positive (QFT-G+) results (18.75%, six of 32) than that with QFT-G-negative (QFT-G(-)) results (0%, 0 of 67; P = .001). Terbium 48-50 thiosulfate sulfurtransferase Homo sapiens 6-9 21143955-14 2010 On the contrary, percentages of positive results in patients with CD4> 200 were 10.9% (6/55), 9.1% (5/55) and 16.4% (9/55) with T-SPOT.TB, QFN-G-IT and TST, respectively. Terbium 138-140 thiosulfate sulfurtransferase Homo sapiens 155-158